Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma

Abstract

Summary The utility of current chemotherapeutic regimens in the treatment of AIDS-related Kaposi 44 (18.5%) had stable disease and two (0.8%) had disease progression. SL-DOX was well tolerated: ten patients discontinued therapy because of adverse events, in four cases because of neutropenia. Grade 3 or 4 neutropenia occurred after 281 of 2023 cycles (13.9%) but involved 137 of 240 patients (57.1%) for whom data were available. SL-DOX has substantial activity in AIDS-KS. Best response is typically seen after fewer than three cycles of chemotherapy and in some cases may be prolonged. The most important adverse event is neutropenia, which occurs after a minority of cycles but which may occur in over half of all patients.

Acoustically-active microbubbles conjugated to liposomes: Characterization of a proposed drug delivery vehicle

“…Liposomes are membrane-enclosed vesicles composed of a lipid bilayer shell (which can trap hydrophobic and amphipathic drugs) surrounding an aqueous core (which can encapsulate hydrophilic drugs) [19][20][21]. In contrast to microbubbles, liposomes have been shown to efficiently carry drugs such as doxorubicin and vincristine [22][23][24], and intravenous injection of drug-carrying liposomes can increase accumulation at the tumor site by 50 to 100 fold compared to the administration of free drug [25][26][27]. Moreover, monodisperse liposomes can be manufactured with an optimized diameter, typically chosen to be near 100 nm to maximize extravasation from tumor vasculature and fusion with cell membranes.…”

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

“…These results can probably be explained by the difference in doses because the adverse effects with this molecule are known to be dose dependent. 28 Wollina et al 17 used 20 mg/m 2 as the dose for 28 patients in their study, 20 to 30 mg/m 2 for 4 patients, and 40 mg/m 2 for 2 patients, whereas all of our patients received a dose of 40 mg/m 2 . In our study we observed 4 serious infections (3 cases of S aureus septicemia and 1 pneumopathy).…”

Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model

“…Impressive response rates to pegylated liposomal chemotherapeutic agents have been obtained in mice bearing mouse mammary tumours and human tumour xenografts (reviewed in Working et al, 1994). In clinical trials, pegylated liposomes containing doxorubicin have been shown to be active against AIDS-related Kaposi's sarcoma, with response rates in excess of either free doxorubicin or conventional combination chemotherapy (Bogner et al, 1994;Harrison et al, 1995;Goebel et al, 1996). Trials of liposomal chemotherapy in patients with a variety of solid tumours are currently under way.…”